QL1706
Drug timelines are a Plus or Pro feature.
80 regulatory and trial events tracked for QL1706, covering 2022-03-02 to 2026-04-21. Get the full timeline:
Most recent: Clinical Trial Update: ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer [Phase 1, Phase 2]